Results 21 to 30 of about 4,230 (200)

Efficacy of ondansetron and palonosetron in prevention of shivering under spinal anesthesia: A prospective randomized double-blind study in patients undergoing elective LSCS

open access: yesJournal of Anaesthesiology Clinical Pharmacology, 2021
Background and Aims: Postanesthesia shivering (PAS) is a common, distressing experience. Ondansetron, the classical 5HT3 antagonist has been in use for its prevention since long.
Manoj K Sharma   +2 more
doaj   +1 more source

Palonosetron-5-HT3Receptor Interactions As Shown by a Binding Protein Cocrystal Structure. [PDF]

open access: yes, 2016
Palonosetron is a potent 5-HT3receptor antagonist and an effective therapeutic agent against emesis. Here we identify the molecular determinants of compound recognition in the receptor binding site by obtaining a high resolution structure of palonosetron
Lillestol, Reidun K   +3 more
core   +1 more source

Acute emesis: moderately emetogenic chemotherapy [PDF]

open access: yes, 2010
This paper is a review of the recommendations for the prophylaxis of acute emesis induced by moderately emetogenic chemotherapy as concluded at the third Perugia Consensus Conference, which took place in June 2009.
Bria, Emilio   +6 more
core   +1 more source

NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK [PDF]

open access: yes, 2017
Background: The objective was to evaluate the cost-effectiveness of NEPA, an oral fixed combination netupitant (NETU, 300 mg) and palonosetron (PA, 0.5 mg) compared with aprepitant and palonosetron (APPA) or palonosetron (PA) alone, to prevent ...
Bourhis, Francois   +7 more
core   +2 more sources

Randomised Control Study of Palonosetron Versus Dexamethasone in Preventing Postoperative Nausea and Vomiting Following Ear and Nose Surgeries under General Anesthesia [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2018
Introduction: Postoperative Nausea and Vomiting (PONV) is defined as any nausea or vomiting that occurs during the first 48 hours after surgery. It is considered as a distressing event following anaesthesia.
Anju Annie Paul   +6 more
doaj   +1 more source

Palonosetron [PDF]

open access: yespharma-kritik, 2008
Wie zum Beispiel Ondansetron wirkt Palonosetron gegen Brechreiz und Erbrechen im Zusammenhang mit emetogener Chemotherapie.
openaire   +1 more source

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting [PDF]

open access: yes, 2016
BACKGROUND We examined the efficacy of olanzapine for the prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Bajaj, Madhuri   +9 more
core   +1 more source

Comparison of efficacy of palonosetron-dexamethasone combination with palonosetron or dexamethasone alone for prophylaxis against post-operative nausea and vomiting in patients undergoing laparoscopic cholecystectomy

open access: yesIndian Journal of Anaesthesia, 2017
Background and Aims: Post-operative nausea and vomiting (PONV) is highly distressing and unpleasant symptom. Dexamethasone and palonosetron are effective antiemetics with minimal side effect profile.
Arindam Chatterjee   +5 more
doaj   +1 more source

Antiemetic research: future directions [PDF]

open access: yes, 2010
PURPOSE AND METHODS: As a part of reviewing the Multinational Association of Supportive Care in Cancer (MASCC) antiemetic guidelines in Perugia in 2009, an expert group identified directions for future antiemetic research.
Aapro, Matti   +5 more
core   +1 more source

Palonosetron has superior prophylactic antiemetic efficacy compared with ondansetron or ramosetron in high-risk patients undergoing laparoscopic surgery: a prospective, randomized, double-blinded study [PDF]

open access: yesKorean Journal of Anesthesiology, 2013
BackgroundPostoperative nausea and vomiting (PONV) continues to be a major problem, because PONV is associated with delayed recovery and prolonged hospital stay.
Sung-Hoon Kim   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy